Cannabidiol as a Novel Therapeutic for Immune Modulation.

IF 6.2 Q1 IMMUNOLOGY

ImmunoTargets and Therapy Pub Date : 2020-08-18 eCollection Date: 2020-01-01 DOI:10.2147/ITT.S263690

Nadia Peyravian, Sapna Deo, Sylvia Daunert, Joaquin J Jimenez

{"title":"Cannabidiol as a Novel Therapeutic for Immune Modulation.","authors":"Nadia Peyravian, Sapna Deo, Sylvia Daunert, Joaquin J Jimenez","doi":"10.2147/ITT.S263690","DOIUrl":null,"url":null,"abstract":"The immune-suppressive effects of cannabidiol (CBD) are attributed to the modulation of essential immunological signaling pathways and receptors. Mechanistic understanding of the pharmacological effects of CBD emphasizes the therapeutic potential of CBD as a novel immune modulator. Studies have observed that the antagonists of CB1 and CB2 receptors and transient receptor potential vanilloid 1 reverse the immunomodulatory effects of CBD. CBD also inhibits critical activators of the Janus kinase/signal transducer and activator of transcription signaling pathway, as well as the nucleotide-binding oligomerization domain-like receptor signaling pathway, in turn decreasing pro-inflammatory cytokine production. Furthermore, CBD protects against cellular damage incurred during immune responses by modulating adenosine signaling. Ultimately, the data overwhelmingly support the immunosuppressive effects of CBD and this timely review draws attention to the prospective development of CBD as an effective immune modulatory therapeutic.","PeriodicalId":30986,"journal":{"name":"ImmunoTargets and Therapy","volume":"9 ","pages":"131-140"},"PeriodicalIF":6.2000,"publicationDate":"2020-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/ITT.S263690","citationCount":"25","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ImmunoTargets and Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/ITT.S263690","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2020/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 25

Abstract

The immune-suppressive effects of cannabidiol (CBD) are attributed to the modulation of essential immunological signaling pathways and receptors. Mechanistic understanding of the pharmacological effects of CBD emphasizes the therapeutic potential of CBD as a novel immune modulator. Studies have observed that the antagonists of CB₁ and CB₂ receptors and transient receptor potential vanilloid 1 reverse the immunomodulatory effects of CBD. CBD also inhibits critical activators of the Janus kinase/signal transducer and activator of transcription signaling pathway, as well as the nucleotide-binding oligomerization domain-like receptor signaling pathway, in turn decreasing pro-inflammatory cytokine production. Furthermore, CBD protects against cellular damage incurred during immune responses by modulating adenosine signaling. Ultimately, the data overwhelmingly support the immunosuppressive effects of CBD and this timely review draws attention to the prospective development of CBD as an effective immune modulatory therapeutic.

Abstract Image

查看原文本刊更多论文

大麻二酚作为一种新的免疫调节药物。

大麻二酚(CBD)的免疫抑制作用归因于必需的免疫信号通路和受体的调节。对CBD药理作用的机制理解强调了CBD作为一种新型免疫调节剂的治疗潜力。研究发现，CB1和CB2受体拮抗剂和瞬时受体电位香草素1逆转了CBD的免疫调节作用。CBD还抑制Janus激酶/信号转导的关键激活因子和转录信号通路的激活因子，以及核苷酸结合寡聚结构域样受体信号通路，从而减少促炎细胞因子的产生。此外，CBD通过调节腺苷信号传导来保护免疫应答过程中发生的细胞损伤。最终，这些数据压倒性地支持CBD的免疫抑制作用，这篇及时的综述引起了人们对CBD作为一种有效免疫调节治疗药物的前景的关注。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

ImmunoTargets and Therapy IMMUNOLOGY-

CiteScore

16.50

自引率

0.00%

发文量

审稿时长

16 weeks

期刊介绍： Immuno Targets and Therapy is an international, peer-reviewed open access journal focusing on the immunological basis of diseases, potential targets for immune based therapy and treatment protocols employed to improve patient management. Basic immunology and physiology of the immune system in health, and disease will be also covered.In addition, the journal will focus on the impact of management programs and new therapeutic agents and protocols on patient perspectives such as quality of life, adherence and satisfaction.